|Day Low/High||170.51 / 179.58|
|52 Wk Low/High||6.26 / 189.40|
Beyond refined fuels, what else is susceptible to sophisticated criminal or terrorist activity? The entire grid? Clean water?
The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.
Here's our updated analysis and trading strategy.
Don't forget, this is a very large company with a lot more than the vaccine going on.
XBI has shown a steep decline from the middle of February.
Plus, the efficacy rate of the still-pending Novavax Covid-19 vaccine against variants of the virus give reason for pause.
Among other things, the president works to align Democratic senators to support his massive Covid relief bill.
Everything came up roses Monday -- except for what matters most, broad participation.
Should we care about Australia's central bank taking overtly aggressive action to reign in the long end of their yield curve? Yes, we should.
* He shoots, he scores - with NVAX (+65% or +$87/share) today Several subscribers have expressed disinterest and even snarkiness in The Smartest Trader in the World's positions -- others like to see his book on almost a daily basis. I posted this up...
I think BA returns to normal as we do, as the airlines do... but with the defense contracting business as a foundation to rely upon.
Can corporate America grow sales for the fourth quarter? Then answer a question with a question.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Penny stocks are for suckers, and six other rules for better investing -- and tuning out the tweet noise.
Most of the indicators are still bullish in this name, although some profit-taking may be occurring.
Short-term traders may want to nail down profits and be careful in their trading strategy with this name.
Isaac Newton's first lesson: An object in motion stays in motion with the same speed and in the same direction unless acted upon by an unbalanced force.
The performance of IWM is telling you that all is not well in the overall U.S. economy.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
This is pretty much exactly what you get when you have so much positive research.
One would need to use covered calls to initiate positions that provide a solid amount of downside protection.
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
Let's review the charts and indicators.
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.